Mr. Alnoor Nathoo reports

MEDBRIGHT AI INVESTMENTS INC. ANNOUNCES SYMBOL CHANGE

Medbright AI Investments Inc. will change its trading symbol to MBAI on the Canadian Securities Exchange (the CSE) and MBAIF on the OTCQB. The company's common shares will begin trading under the new symbols on the OTCQB as of Nov. 17, 2023 and on the CSE as of Nov. 21, 2023.

No further action is required by existing shareholders with respect to the symbol change. The Cusip/ISIN for the company's common shares will remain the same, and there is no change in the share capital of the company. Certificates representing common shares of the company will not be affected by the symbol change and will not need to be exchanged.

The company also announces that it has entered into an investor relations agreement dated Nov. 15, 2023, with Triomphe Holdings Ltd., doing business as Capital Analytica, an arm's-length party with respect to the company. Pursuant to the agreement, Capital Analytica has agreed to provide investor relations and communications services to the company in exchange for an aggregate amount of $60,000. The services will include continuing social media consultation regarding engagement and enhancement, social sentiment reporting, social engagement reporting, discussion forum monitoring and reporting, corporate video dissemination, and other related investor relations services. The term of the Capital Analytica agreement is for a period of three months.

About Medbright AI Investments Inc.

Medbright AI is a capital allocator focused on investing in health care technology companies. The team at Medbright prides themselves on unparallelled access to opportunities, as well as structuring unique and advantageous investments. Medbright's mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. Medbright will focus on significant near-term and mid-term high-quality opportunities with strong return potentials while maintaining commitment to governance.